EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers

OBJECTIVE: Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between outcome and EGFR copy number (CN) in pretreatment tissue and plasma cell-free DNA (c...

Descripción completa

Detalles Bibliográficos
Autores principales: Smyth, Elizabeth C, Vlachogiannis, Georgios, Hedayat, Somaieh, Harbery, Alice, Hulkki-Wilson, Sanna, Salati, Massimiliano, Kouvelakis, Kyriakos, Fernandez-Mateos, Javier, Cresswell, George D, Fontana, Elisa, Seidlitz, Therese, Peckitt, Clare, Hahne, Jens C, Lampis, Andrea, Begum, Ruwaida, Watkins, David, Rao, Sheela, Starling, Naureen, Waddell, Tom, Okines, Alicia, Crosby, Tom, Mansoor, Was, Wadsley, Jonathan, Middleton, Gary, Fassan, Matteo, Wotherspoon, Andrew, Braconi, Chiara, Chau, Ian, Vivanco, Igor, Sottoriva, Andrea, Stange, Daniel E, Cunningham, David, Valeri, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Upper GI cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355876/
https://www.ncbi.nlm.nih.gov/pubmed/33199443
http://dx.doi.org/10.1136/gutjnl-2020-322658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355876/
https://www.ncbi.nlm.nih.gov/pubmed/33199443
http://dx.doi.org/10.1136/gutjnl-2020-322658

Ejemplares similares